SCHEMBL5136897

SCHEMBL5136897

CCCCn1c(CN(CCc2ccc(C)cc2)Cc2ccc3c(c2)OCO3)cnc1-c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.55
TP53 P04637 3/20 0.43
POLB P06746 1/20 0.43
HTR2A P28223 3/20 0.42
HTR2C P28335 3/20 0.42
HTR2B P41595 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
TDP1 Q9NUW8 1/20 0.42
TSHR P16473 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
LMNA P02545 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
ADRB1 P08588 1/20 0.41
HTR1A P08908 1/20 0.41
ADRA2A P08913 1/20 0.41
DRD2 P14416 1/20 0.41
ADRA2B P18089 1/20 0.41
ADRA2C P18825 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4766677 0.97 C5AR1 (0.56) C5AR1TP53POLBHTR2AHTR2C
SCHEMBL5136535 0.96 C5AR1 (0.57) C5AR1TP53POLBHTR2AHTR2C
SCHEMBL5135700 0.93 C5AR1 (0.53) C5AR1TP53POLBHTR2AHTR2C
SCHEMBL5134794 0.93 C5AR1 (0.53) C5AR1TP53POLBHTR2AHTR2C
SCHEMBL5135111 0.93 C5AR1 (0.54) C5AR1TP53POLBHTR2AHTR2C
SCHEMBL5073883 0.93 C5AR1 (0.58) C5AR1TP53POLBHTR2AHTR2C
SCHEMBL4765554 0.92 C5AR1 (0.59) C5AR1TP53POLBHTR2AHTR2C
SCHEMBL4770879 0.92 C5AR1 (0.59) C5AR1TP53POLBHTR2AHTR2C
SCHEMBL5135671 0.92 C5AR1 (0.52) C5AR1TP53POLBHTR2AHTR2C
SCHEMBL5136131 0.92 C5AR1 (0.52) C5AR1TP53POLBHTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed